JP6607976B2 - Foreign eye feel relief eye drops - Google Patents

Description

  The present invention relates to eye drops.

  The cornea is a tissue composed of five layers of the corneal epithelium, Bowman's membrane, corneal stroma, Descemet's membrane, and corneal endothelium in order from the outside, and is configured on the outermost surface of the eyeball. Due to anatomical features that are in direct contact with the outside world, various foreign substances such as antigens, microorganisms, and dust are likely to enter. On the other hand, most sensory nerves distributed in the cornea are trigeminal nerves. The perception of the cornea is regarded as one of the most sensitive pain perceptions of the human body, and the degree of pain is extremely sharp. In other words, the nerve endings end just below the corneal epithelium, and even a slight loss or detachment of the corneal epithelium exposes and stimulates the nerve endings just below the corneal epithelium, so it feels as strong pain (non-) Patent Document 1).

  In this way, because the cornea is very painful, even if foreign substances such as dust, pollen, and excessive amounts of protein adhere to the corneal epithelium, they immediately appear as symptoms such as foreign body sensation and eye pain. In some cases, tearing may occur to discharge foreign matter. That is, it is important from the viewpoint of removing indefinite complaints and improving the quality of life to improve the adhesion of foreign matter to the surface of the eyeball such as protein stains and the resulting foreign matter sensation.

  In recent years, not only dust, pollen and protein stains, but also eyes caused by dirt such as cosmetics (mascara, eyeliner, eye shadow, lotion, milky lotion, eye cream, lame cosmetic, scrub facial cleanser, etc.) The feeling of foreign objects and eye damage are also serious problems. In order to wash and remove cosmetics or pollen adhering to the eyeball or eyelid, an eyewash having a monoterpene contained in a carboxyvinyl polymer and brought into contact with a site to be washed at a time is 500 μL (patent) Reference 1).

  The foreign body sensation of the eye is one of the subjective symptoms that are particularly likely to occur as one of allergic symptoms. When external allergens such as pollen and house dust are in direct contact with the cornea, proteins such as the skin stratum corneum or proteins secreted from the eyes are mixed into the eye conjunctiva by rubbing the eyes during pruritus. Increased oxidation and adsorption to the cornea. Also, at the onset of allergic conjunctival disease, the conjunctival papilla, which is a hypertrophic change of the conjunctival epithelial layer, is formed, and many conjunctival papilla touches the cornea at the time of blinking, so a sense of foreign body is often felt (non- Patent Document 2). The protein adsorbed on the cornea not only gives a sense of foreign matter, but may also damage the cornea.

  Pranoprofen and / or its salts are known as propionic acid non-steroidal anti-inflammatory agents having excellent anti-inflammatory, analgesic and antipyretic effects, and are highly safe. Widely used as an agent.

  However, at present, the effect on the foreign body sensation of the eye when pranoprofen is used in combination with an antiallergic agent, an anti-inflammatory agent or a water-soluble vitamin cannot be predicted at all.

JP 2011-93889 A

Takehisa Kondo: Neural nerve, monthly ophthalmology practice 72:30, 2001 Japan Ophthalmology Allergy Study Group: Guidelines for Medical Treatment of Allergic Conjunctivitis Disease (2nd Edition), Journal of the Japanese Ophthalmological Society, Vol. 114, No. 10: 839-846, 2010

  An object of the present invention is to provide an eye drop that can alleviate the feeling of foreign matter in the eye by suppressing foreign matter adsorption to the cornea.

  As a result of intensive studies to solve the above problems, the present inventors have found that (A) pranoprofen or a salt thereof (hereinafter also referred to as “component (A)”), (B) an antiallergic agent, The present inventors have found that the combination of at least one selected from the group consisting of an inflammatory agent and a water-soluble vitamin (hereinafter also referred to as “component (B)”) alleviates the feeling of foreign matter in the eye. In addition, the present inventors have found that (C) a refreshing agent is combined to remarkably reduce the feeling of foreign matter. Based on these findings, the present inventors have completed the present invention.

That is, the present invention provides the following [1] to [10].
[1] A foreign substance sensation alleviating eye drop containing (A) pranoprofen or a salt thereof and (B) at least one compound selected from the group consisting of an antiallergic agent, an anti-inflammatory agent and a water-soluble vitamin. ;
[2] The foreign body sensation alleviating eye drop according to [1], wherein the foreign body sensation is a foreign body sensation as an allergic symptom;
[3] The foreign body sensation according to [1] or [2], comprising as component (B) at least one antiallergic agent selected from the group consisting of cromoglycic acid, pemirolast, tranilast, olopatadine, and salts thereof Relief eye drops;
[4] As component (B), at least one selected from the group consisting of ε-aminocaproic acid, allantoin, berberine sulfate, berberine chloride, dipotassium glycyrrhizinate, sodium azulenesulfonate, zinc sulfate, zinc lactate and lysozyme chloride. A foreign substance sensation alleviating eye drop according to any one of [1] to [3], comprising the anti-inflammatory agent;
[5] The component (B) contains at least one water-soluble vitamin selected from the group consisting of pyridoxine hydrochloride, cyanocobalamin, flavin adenine dinucleotide sodium, panthenol, calcium pantothenate and sodium pantothenate, [1] To [4] a foreign substance sensation alleviating eye drop;
[6] When the antiallergic agent is contained as the component (B) with respect to 1 part by mass of the total content of the component (A), the total content of the antiallergic agent is 0.05 to 200 parts by mass, (B) When the component contains an anti-inflammatory agent, the total content of the anti-inflammatory agent is 0.02 to 200 parts by weight. When the component (B) contains a water-soluble vitamin, the total content of the water-soluble vitamin is 0.002. The eye drop according to any one of [1] to [5], which is ˜20 parts by mass.
[7] (C) A foreign substance sensation alleviating eye drop according to any one of [1] to [6], further comprising a cooling agent;
[8] The foreign substance sensation alleviating eye drop according to [7], which contains at least one refreshing agent selected from the group consisting of menthol, camphor, borneol, geraniol and mint oil as the component (C);
[9] The instillation according to [7] or [8], wherein the total content of the (C) cooling agent is 0.0002 to 5 parts by mass with respect to 1 part by mass of the total content of the component (A). Agent.
[10] The foreign substance sensation alleviating eye drop according to any one of [1] to [9], which is applied without wearing a silicone hydrogel contact lens;
[11] A foreign substance comprising a combination of (A) pranoprofen or a salt thereof and (B) at least one compound selected from the group consisting of an antiallergic agent, an anti-inflammatory agent, and a water-soluble vitamin. A method of imparting a feeling relieving effect to eye drops.
[12] The method according to [11], further comprising (C) a cooling agent.

  According to the foreign substance sensation alleviating eye drop according to the present invention, at least one compound selected from the group consisting of (A) pranoprofen or a salt thereof and (B) an antiallergic agent, an antiinflammatory agent and a water-soluble vitamin. In combination, it is possible to alleviate the feeling of foreign objects in the eye caused by allergies and the like by suppressing the adsorption of foreign substances to the cornea. Furthermore, the combination of the components (A) and (B) further includes (C) a cooling agent, thereby further suppressing the adsorption of foreign matter to the cornea, thereby reducing the sense of foreign matter in the eye caused by allergies. It can be more relaxed.

  In the present specification, the unit of content “%” means “w / v%” and is synonymous with “g / 100 mL”.

  In the present specification, “foreign body sensation” means subjective symptoms such as rash or tingling caused by dry eyes, inappropriate use of contact lenses, allergic conjunctivitis due to adhesion of foreign substances such as pollen and house dust, etc. To do. Therefore, the present inventors have focused on suppressing the adhesion of foreign substances and improving subjective symptoms in order to alleviate the feeling of foreign substances. In particular, suppressing the adhesion of foreign substances has a preventive effect on the feeling of foreign objects in the eyes.

  The foreign substance sensation alleviating eye drop according to the present embodiment (hereinafter, also simply referred to as the eye drop according to the present embodiment) includes (A) pranoprofen or a salt thereof, and (B) an antiallergic agent, an anti-inflammatory agent, and a water-soluble agent. And at least one compound selected from the group consisting of vitamins.

(A) Component Planoprofen is (2RS) -2- (10H-9-oxa-1-azaanthracen-6-yl) -propanoic acid or α-methyl-5H- [1] benzopyrano [2,3 -B] It is a known compound also called pyridine-7-acetic acid, and what was synthesize | combined by the well-known method may be used, and it is also possible to obtain as a commercial item.

  The salt of pranoprofen is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Specific examples of such salts include salts with inorganic bases [eg, ammonium salts; salts with metals such as alkali metals (sodium, potassium, etc.), alkaline earth metals (calcium, magnesium, etc.), aluminum] And salts with organic bases [for example, salts with organic amines such as methylamine, triethylamine, diethylamine, triethanolamine, morpholine, piperazine, pyrrolidine, tripyridine, and picoline] and the like. Planoprofen or a salt thereof includes a hydrate form.

  As the component (A) used in the aqueous composition according to this embodiment, from pranoprofen or a salt thereof, one kind may be used alone, or two or more kinds may be used in any combination. good. Of these, pranoprofen is suitable as the component (A).

  The content of the component (A) in the eye drop according to the present embodiment is not particularly limited, and is appropriately set according to the type of the component (A), the type and content of the component (B) to be used together. As content of (A) component, it is preferable that content of (A) component is 0.001-0.5 w / v% on the basis of the total amount of the eyedrops which concern on this embodiment, for example, It is more preferably 0.002 to 0.2 w / v%, further preferably 0.005 to 0.1 w / v%, and particularly preferably 0.01 to 0.1 w / v%. . The content of the component (A) is suitable from the viewpoint of the effect of reducing the feeling of foreign matter.

(B) component (B) component is at least 1 type of compound selected from the group which consists of an antiallergic agent, an anti-inflammatory agent, and a water-soluble vitamin. (B) A component may be used individually by 1 type and may be used in combination of 2 or more types arbitrarily.

  The antiallergic agent is not particularly limited as long as it can suppress an allergic reaction. For example, cromoglycic acid, amlexanox, ibudilast, suplatast, pemirolast, tranilast, olopatadine, acitazanolast, ketotifen and salts thereof (for example, Cromoglycate, sodium pemirolast, olopatadine hydrochloride, ketotifen fumarate), and cromoglycic acid, pemirolast, tranilast, olopatadine and their salts are preferred from the viewpoint of the effect of alleviating foreign body feeling, and tranilast or olopatadine Hydrochloride is particularly preferred.

  When the antiallergic agent is contained in the eye drop according to the present embodiment, the content of the antiallergic agent is not particularly limited, and is appropriately set according to the type of the antiallergic agent, the content of the component (A) to be used in combination. The As the content of the antiallergic agent, for example, the total content of the antiallergic agent is preferably 0.005 to 3 w / v% based on the total amount of the eye drops according to the present embodiment, and 0.01 It is more preferably ˜2 w / v%, further preferably 0.05 to 1 w / v%, and particularly preferably 0.1 to 1 w / v%. The content of the antiallergic agent is suitable from the viewpoint of the effect of reducing the feeling of foreign matter.

  Moreover, the content ratio of the antiallergic agent to the component (A) in the eye drop according to the present embodiment is not particularly limited, and is appropriately set according to the type of the antiallergic agent and the like. As the content ratio of the antiallergic agent to the component (A), for example, the total content of the antiallergic agent is 0 with respect to 1 part by mass of the component (A) contained in the eye drop according to this embodiment. 0.05 to 200 parts by mass, more preferably 0.2 to 50 parts by mass, still more preferably 0.5 to 30 parts by mass, and particularly preferably 1 to 20 parts by mass. preferable. The content ratio of the antiallergic agent relative to the component (A) is suitable from the viewpoint of the effect of reducing the feeling of foreign matter.

  Examples of the anti-inflammatory agent include glycyrrhizic acid, allantoin, berberine sulfate, berberine chloride, azulene sulfonic acid, ε-aminocaproic acid, zinc sulfate, zinc lactate, lysozyme, salicylic acid, tranexamic acid and licorice. The anti-inflammatory agent may be in the form of a salt such as a salt with an inorganic acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, and a sulfate. , Lactate, hydrochloride, chloride salt, sodium salt, potassium salt and the like. Specific examples include dipotassium glycyrrhizinate, sodium azulene sulfonate, lysozyme chloride and the like. From the viewpoint of the effect of reducing the feeling of foreign matter, dipotassium glycyrrhizinate, allantoin, berberine sulfate, berberine chloride, sodium azulenesulfonate, ε-aminocaproic acid, zinc sulfate, zinc lactate or lysozyme chloride is preferable, ε-aminocaproic acid, Allantoin, berberine sulfate or dipotassium glycyrrhizinate is particularly preferred.

  When the anti-inflammatory agent is contained in the eye drop according to this embodiment, the content of the anti-inflammatory agent is not particularly limited, and is appropriately set according to the type of the anti-inflammatory agent, the content of the component (A) to be used together, and the like. The As the content of the anti-inflammatory agent, for example, the total content of the anti-inflammatory agent is preferably 0.001 to 7.5 w / v% based on the total amount of the eye drop according to the present embodiment, and 0 It is more preferably 0.004 to 5 w / v%, still more preferably 0.01 to 1 w / v%, and particularly preferably 0.02 to 0.5 w / v%. The content of the anti-inflammatory agent is suitable from the viewpoint of the effect of reducing the feeling of foreign matter.

  Further, the content ratio of the anti-inflammatory agent to the component (A) in the eye drop according to the present embodiment is not particularly limited, and is appropriately set according to the type of the anti-inflammatory agent. The content ratio of the anti-inflammatory agent to the component (A) is, for example, that the total content of the anti-inflammatory agent is 0 with respect to 1 part by mass of the component (A) contained in the eye drop according to the present embodiment. It is preferably 0.02 to 200 parts by mass, more preferably 0.05 to 100 parts by mass, still more preferably 0.2 to 20 parts by mass, and 0.5 to 10 parts by mass. Is particularly preferred. The content ratio of the anti-inflammatory agent with respect to the component (A) is preferable from the viewpoint of the effect of reducing the feeling of foreign matter.

Examples of the water-soluble vitamin include vitamin C and vitamin B group. Examples of the vitamin B group include vitamin B ₁ , vitamin B ₂ (flavin adenine dinucleotide sodium), niacin (nicotinic acid and nicotinic acid amide), pantothenic acid, panthenol, vitamin B ₆ (pyridoxine, pyridoxal and pyridoxamine), Biotin, folic acid and vitamin B ₁₂ (cyanocobalamin, hydroxocobalamin, methylcobalamin and adenosylcobalamin). The water-soluble vitamin may be in the form of a salt, and examples include pyridoxine hydrochloride, calcium pantothenate, and sodium pantothenate. From the viewpoint of the effect of reducing the feeling of foreign matter, pyridoxine hydrochloride, cyanocobalamin, flavin adenine dinucleotide sodium, panthenol, calcium pantothenate or sodium pantothenate is preferred, and pyridoxine hydrochloride or cyanocobalamin is particularly preferred.

  When the eye drop according to the present embodiment contains a water-soluble vitamin, the content of the water-soluble vitamin is not particularly limited, and is appropriately set according to the type of the water-soluble vitamin, the content of the component (A) to be used in combination. The As the content of the water-soluble vitamin, for example, the total content of the water-soluble vitamin is preferably 0.001 to 1 w / v% based on the total amount of the eye drops according to the present embodiment, and 0.001 More preferably, it is -0.5 w / v%, It is still more preferable that it is 0.003-0.3 w / v%, It is especially preferable that it is 0.01-0.2 w / v%. The content of the water-soluble vitamin is preferable from the viewpoint of the effect of reducing the feeling of foreign matter.

  Moreover, the content ratio of the water-soluble vitamin with respect to the component (A) in the eye drop according to this embodiment is not particularly limited, and is appropriately set according to the type of the water-soluble vitamin. As the content ratio of the water-soluble vitamin to the component (A), for example, the total content of the water-soluble vitamin is 0 with respect to 1 part by mass of the component (A) contained in the eye drop according to the present embodiment. It is preferably 0.002 to 20 parts by mass, more preferably 0.01 to 10 parts by mass, still more preferably 0.03 to 6 parts by mass, and 0.1 to 4 parts by mass. Is particularly preferred. The content ratio of the water-soluble vitamin with respect to the component (A) is preferable from the viewpoint of the effect of reducing the feeling of foreign matter.

(C) Component The eye drop according to the present embodiment may further contain (C) a cooling agent. By containing (C) component, the foreign-materials feeling mitigation effect | action of eyedrops increases.

  The refreshing agent used in the foreign substance sensation alleviating eye drop according to the present embodiment is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of the refreshing agent include terpenoids, essential oils containing terpenoids (eg, eucalyptus oil, bergamot oil, peppermint oil, fennel oil, rose oil, cinnamon oil, spearmint oil, camphor oil, cool mint and mint oil). Can be mentioned. Examples of terpenoids include menthol, menthone, camphor (also referred to as “camphor” or “camphor”), borneol (also referred to as “ryuuno” or “columbum”), geraniol, nerol, cineol, citronellol, carvone, anethole, eugenol, Examples include limonene, linalool and linalyl acetate. The terpenoid may be any of d-form, l-form and dl-form, and examples thereof include l-menthol, d-menthol, dl-menthol, dl-camphor, d-camphor, dl-borneol and d-borneol. However, optical isomers may not exist depending on terpenoids such as geraniol, nerol and cineol. Menthol, camphor, borneol, geraniol or mint oil is preferred from the viewpoint of the effect of reducing the feeling of foreign matter, and l-menthol, dl-camphor or d-borneol is particularly preferred.

  The content of the refreshing agent in the eye drop according to the present embodiment is not particularly limited, and is appropriately set according to the type of the refreshing agent, the type and content of the component (A) and the component (B) used together. . The content of the refreshing agent can be measured as a terpenoid. For example, the total content of the refreshing agent (as a terpenoid) is 0.00002-0 based on the total amount of the eyedrops according to the present embodiment. 0.3 w / v% is preferable, 0.0001 to 0.1 w / v% is more preferable, 0.0005 to 0.05 w / v% is further preferable, and 0.001 to 0 is preferable. Particularly preferred is 0.02 w / v%. The content of the refreshing agent is suitable from the viewpoint of the effect of reducing the feeling of foreign matter.

  Moreover, the content rate of the refreshing agent with respect to (A) component in the eye drop which concerns on this embodiment is not specifically limited, It sets suitably according to the kind etc. of refreshing agent. As a content ratio of the refreshing agent with respect to the component (A), for example, the total content of the refreshing agent is 0 with respect to 1 part by mass of the component (A) contained in the eye drop according to this embodiment. It is preferably .0002 to 5 parts by mass, more preferably 0.002 to 2 parts by mass, still more preferably 0.005 to 1 part by mass, and 0.02 to 0.5 parts by mass. It is particularly preferred. The content ratio of the water-soluble vitamin with respect to the component (A) is preferable from the viewpoint of the effect of reducing the feeling of foreign matter.

  The eye drop according to the present embodiment can further contain a surfactant. A surfactant is a solubilizing agent that improves the solubility of various pharmacologically active ingredients, physiologically active ingredients, additives, and the like, which will be described later, depending on the purpose of use of the eye drop according to this embodiment. It is effective as

  The surfactant that can be contained in the eye drop according to the present embodiment is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable, and is nonionic surfactant. Either an agent or an ionic (amphoteric, negative, positive) surfactant may be used.

  Specific examples of the nonionic surfactant that can be contained in the ophthalmic solution according to the present embodiment include monouraric acid POE (20) sorbitan (polysorbate 20), monopalmitic acid POE (20) sorbitan (polysorbate 40). POE sorbitan fatty acid esters such as monostearic acid POE (20) sorbitan (polysorbate 60), tristearic acid POE (20) sorbitan (polysorbate 65), monooleic acid POE (20) sorbitan (polysorbate 80); POE (40) Hardened castor oil (polyoxyethylene hardened castor oil 40), POE hardened castor oil such as POE (60) hardened castor oil (polyoxyethylene hardened castor oil 60); POE (10) castor oil (polyoxyethylene castor oil 10) , POE (35) castor POE castor oil such as (polyoxyethylene castor oil 35); POE alkyl ether such as POE (9) lauryl ether; POE-POP alkyl ether such as POE (20) POP (4) cetyl ether; POE (196) POP ( 67) Polyoxyethylene / polyoxypropylene block copolymers such as glycol (poloxamer 407, Pluronic F127), POE (200) POP (70) glycol; polyethylene glycol monostearate such as polyoxyl 40 stearate and the like. In the compounds exemplified above, the numbers in parentheses indicate the number of added moles.

  As the nonionic surfactant, POE sorbitan fatty acid ester, POE hydrogenated castor oil, POE castor oil, polyethylene glycol monostearate or POE / POP block copolymer are preferable, polysorbate 80, POE castor oil 10, POE castor oil 35, More preferred are POE hydrogenated castor oil 40, POE hydrogenated castor oil 60, polyoxyl 40 stearate or poloxamer 407.

  As the amphoteric surfactant that can be contained in the eye drop according to the present embodiment, specifically, N- [2-[[2- (alkylamino) ethyl] amino] ethyl] glycine and a salt thereof (for example, Hydrochloride, etc.). N- [2-[[2- (alkylamino) ethyl] amino] ethyl] glycine is also referred to as alkyldiaminoethylglycine or alkylpolyaminoethylglycine.

  Further, the anionic surfactant that can be contained in the eye drop according to the present embodiment, specifically, alkylbenzene sulfonate, alkyl sulfate, polyoxyethylene alkyl sulfate, α-sulfo fatty acid ester salt And α-olefin sulfonic acid.

  Specific examples of the cationic surfactant that can be contained in the eye drops according to the present embodiment include benzalkonium chloride and benzethonium chloride.

  In the eye drop according to the present embodiment, the surfactant may be used alone or in combination of two or more. Among the surfactants that can be contained in the eye drops according to the present embodiment, nonionic surfactants are preferable.

  When the ophthalmic solution according to the present embodiment contains a surfactant, the content thereof includes the type of the surfactant, the type and content of other compounding components, the use of the ophthalmic composition, the formulation form, and the use It is set appropriately according to the method and the like. As the content of the surfactant, for example, the total content of the surfactant is preferably 0.001 to 3 w / v% based on the total amount of the ophthalmic composition according to the present embodiment. It is more preferably 005 to 2 w / v%, further preferably 0.01 to 1 w / v%, and particularly preferably 0.05 to 1 w / v%.

  The eye drop according to this embodiment preferably further contains a buffer. Thereby, pH of eyedrops can be adjusted and the effect of this application can be exhibited more notably.

  The buffer is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of the buffer include borate buffer, phosphate buffer, carbonate buffer, citrate buffer, acetate buffer, tris buffer, aspartic acid, aspartate, edetate, and the like. These buffering agents may be used alone or in any combination of two or more. Examples of the boric acid buffer include boric acid or a salt thereof (alkali metal borate, alkaline earth metal borate, etc.). Examples of the phosphate buffer include phosphoric acid or a salt thereof (such as an alkali metal phosphate or an alkaline earth metal phosphate). Examples of the carbonate buffer include carbonic acid or a salt thereof (an alkali metal carbonate, an alkaline earth metal carbonate, etc.). Examples of the citrate buffer include citric acid or salts thereof (alkali metal citrate, alkaline earth metal citrate, etc.). Moreover, you may use the borate or the hydrate of a phosphate as a borate buffer or a phosphate buffer. As a more specific example, boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, ammonium borate, borax, etc.); as a phosphate buffer, phosphoric acid or a salt thereof Salt (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, tripotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, etc.); Or a salt thereof (sodium bicarbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium bicarbonate, magnesium carbonate, etc.); citric acid or a salt thereof (sodium citrate, potassium citrate, citric acid, etc.) Acid calcium, sodium dihydrogen citrate, disodium citrate, etc.); acetic acid Agents as, acetic acid or a salt thereof (ammonium acetate, potassium acetate, calcium acetate, sodium acetate, etc.); aspartic acid or a salt thereof (sodium aspartate, magnesium aspartate, potassium aspartate, etc.), and others. Among these buffering agents, boric acid buffering agents (for example, a combination of boric acid and borax) or phosphoric acid buffering agents (for example, a combination of disodium hydrogen phosphate and sodium dihydrogen phosphate) are preferable. An acid buffer is more preferred.

  When a buffering agent is blended in the foreign substance sensation alleviating eye drop according to the present embodiment, the content is the type of the buffering agent, the type and content of other compounding ingredients, the use of the foreign substance sensation alleviating eye drop, and the formulation form It is set as appropriate according to the method of use. As the content of the buffering agent, for example, the total content of the buffering agent is preferably 0.01 to 15 w / v% based on the total amount of the foreign substance sensation alleviating eye drop according to the present invention. More preferably, it is 05-10 w / v%, It is further more preferable that it is 0.1-7.5 w / v%, It is especially preferable that it is 0.5-5 w / v%.

  The pH of the foreign substance sensation alleviating eye drop according to the present embodiment is not particularly limited as long as it is within a range that is pharmaceutically, pharmacologically (pharmaceutically), or physiologically acceptable. The range of the pH of the foreign substance sensation alleviating eye drop according to the present invention is 4.0 to 9.5, preferably 5.0 to 9.0, and more preferably 5.5 to 8.5. When the pH is in the above range, there is little irritation to the eyes when using the eye drops, and the foreign body sensation tends to be more relaxed.

  The isotonic agent is not particularly limited as long as it is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable. Examples of isotonic agents include disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, sodium hydrogen sulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, acetic acid. Sodium, sodium hydrogen carbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, glycerin, propylene glycol, polyethylene glycol, glucose, mannitol, sorbitol and the like can be mentioned. Among these isotonic agents, glycerin, propylene glycol, polyethylene glycol, glucose, sodium chloride, potassium chloride, calcium chloride or magnesium chloride are preferable, sodium chloride, potassium chloride or propylene glycol is more preferable, and sodium chloride is particularly preferable. . These isotonic agents may be used alone or in any combination of two or more.

  When the eye drop according to the present embodiment contains an isotonic agent, the content is appropriately set according to the type of tonicity agent, the type and content of other components. As the content of the tonicity agent, for example, the total content of the tonicity agent is preferably 0.01 to 10 w / v%, based on the total amount of eye drops, and 0.05 to 5 w / v. It is more preferable that it is v%, and it is still more preferable that it is 0.1-3 w / v%.

  In addition, the osmotic pressure of the eye drop according to the present embodiment is not particularly limited as long as it is within the range allowed by the living body. The osmotic pressure ratio of the eye drop is, for example, preferably 0.5 to 5.0, more preferably 0.6 to 3.0, and still more preferably 0.7 to 2.0. 0.9 to 1.55 is particularly preferable. The osmotic pressure can be adjusted by a method known in the art using an inorganic salt, a polyhydric alcohol, a sugar alcohol or a sugar. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (0.9 w / v% sodium chloride aqueous solution) based on the 16th revised Japanese Pharmacopoeia. Measure with reference to (freezing point depression method). In addition, about the standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution), after drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500-650 degreeC for 40-50 minutes, it is in a desiccator (silica gel). It is allowed to cool, and 0.900 g is accurately weighed and dissolved in purified water to make exactly 100 mL, or a commercially available standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution) can be used. .

  The eye drop according to this embodiment preferably further contains a thickener. Thereby, the viscosity of the eyedrops according to the present embodiment can be adjusted, and the effects of the present application can be exhibited more remarkably.

  Examples of the thickener include polyvinyl alcohol (completely or partially saponified product), polyvinylpyrrolidone (K25, K30, K90, etc.), carboxyvinyl polymer, cellulose derivatives [methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose. (2208, 2906, 2910, etc.), carboxymethylcellulose, carboxyethylcellulose, nitrocellulose or their salts], polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 1500, Macrogol 4000, Macrogol 6000, etc.), chondroitin Sodium sulfate, sodium hyaluronate, gum arabic, tragacanth, dextran (40, 70, etc.), Examples thereof include sucrose and sorbitol, preferably polyvinyl alcohol (completely or partially saponified product), polyvinylpyrrolidone (K25, K30, K90), carboxyvinyl polymer, cellulose derivative (methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose) (2208, 2906, 2910), carboxymethylcellulose or a salt thereof), polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 4000, Macrogol 6000, etc.) or dextran (70), more preferably polyvinyl alcohol ( Fully or partially saponified), polyvinylpyrrolidone (K25, K30, K90), carboxyvinyl polymer, methylcellulose, Mud carboxymethyl cellulose, hydroxypropyl methylcellulose (2208, 2906, 2910), carboxymethyl cellulose or a salt thereof, polyethylene glycol (Macrogol 300, Macrogol 400, Macrogol 4000, Macrogol 6000) or dextran (70). From the viewpoint of preventing allergic symptoms and / or enhancing the corneal epithelial barrier function, polyvinylpyrrolidone, hydroxyethylcellulose or hydroxypropylmethylcellulose is more preferred, and polyvinylpyrrolidone is particularly preferred. These thickening agents may be used alone or in any combination of two or more.

  When the eye drop which concerns on this embodiment contains a thickener, the content is suitably set according to the kind of thickener, the kind and content, etc. of another content component. As the content of the viscous agent, for example, the total content of the viscous agent is preferably 0.0001 to 5 w / v%, based on the total amount of eye drops, and is preferably 0.0005 to 3 w / v%. It is more preferable that it is 0.001-1 w / v%, and it is especially preferable that it is 0.01-0.2 w / v%.

  The viscosity of the eye drop according to the present embodiment is not particularly limited as long as it is within a range acceptable for a living body. The viscosity at 25 ° C. measured with a rotational viscometer (RE550 type viscometer, manufactured by Toki Sangyo Co., Ltd., rotor: 1 ° 34 ′ × R24) is preferably 0.1 to 1000 mPa · s, for example, 0.5 More preferably, it is -100 mPa * s, and it is still more preferable that it is 1-10 mPa * s.

In addition, the eye drop according to the present embodiment may contain an appropriate amount of various pharmacologically active components or physiologically active components in addition to the above components as long as the effects of the present invention are not hindered. Such components are not particularly limited, and examples thereof include active ingredients in various pharmaceuticals described in the OTC Drug Manufacturing and Sales Approval Standards 2012 edition (supervised by the Japanese Society for Regulatory Science). Specifically, the following components are listed as components used in ophthalmic drugs.
Antihistamine: chlorpheniramine maleate, diphenhydramine hydrochloride, ketotifen fumarate decongestant: tetrahydrozoline hydrochloride, tetrahydrozoline nitrate, nafazoline hydrochloride, naphazoline nitrate, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, phenylephrine hydrochloride, dl-methylephedrine hydrochloride, etc. .
Eye muscle modulating agent: for example, cholinesterase inhibitor having an active center similar to acetylcholine, specifically, neostigmine methyl sulfate, tropicamide, helenien, atropine sulfate, etc.
Bactericides: for example, acrinol, cetylpyridinium, benzalkonium chloride, benzethonium chloride, chlorhexidine, polyhexamethylene biguanide, alkyldiaminoethylglycine hydrochloride, etc.
Amino acids: glycine, alanine, γ-aminobutyric acid, aspartic acid, potassium L-aspartate, glutamic acid, arginine, lysine, aminoethylsulfonic acid (taurine) chondroitin sulfate, sodium chondroitin sulfate, sodium hyaluronate, alginic acid and the like. However, ε-aminocaproic acid is excluded.
Vitamins: retinol acetate, retinol palmitate, tocopherol acetate, etc.
Other: For example, sulfamethoxazole, sulfamethoxazole sodium and the like.

In addition, for the eye drops according to the present embodiment, various additives are appropriately selected according to a conventional method according to the use or formulation form, as long as the effects of the invention are not impaired. And may be contained in an appropriate amount. Examples of these additives include various additives described in Pharmaceutical Additives Encyclopedia 2007 (edited by Japan Pharmaceutical Additives Association). Typical additives include the following additives.
Carrier: An aqueous carrier such as water or hydrous ethanol.
Sugars: for example, glucose, cyclodextrin and the like.
Sugar alcohols: For example, xylitol, sorbitol, mannitol and the like. These may be any of D-form, L-form and DL-form.
Preservatives, bactericides or antibacterials: for example, zinc chloride, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, dehydroacetic acid Sodium, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexamethylene biguanide, polyhexanide hydrochloride, etc.), Glow Kill (trade name, manufactured by Rhodia).
Stabilizers: trometamol, sodium formaldehyde sulfoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, glyceryl monostearate, dibutylhydroxytoluene, sodium edetate, etc.

  The eye drop according to the present embodiment is prepared by adding the above components (A) and (B) and other components as necessary to the carrier so as to have a desired content. Specifically, for example, the components can be dissolved or suspended in purified water, adjusted to a predetermined pH and osmotic pressure, and sterilized by filtration sterilization or the like.

  In the eye drop according to the present embodiment, the water content is 85 w / v% or more, preferably 90 w / v% or more, and preferably 92 w / v% or more with respect to the total amount of eye drops. Is more preferably 94 w / v% or more, and particularly preferably 96 w / v% or more. As the water used in the eye drop according to the present embodiment, water that is pharmaceutically, pharmacologically (pharmaceutically) or physiologically acceptable may be used. Specifically, as such water, Examples include distilled water, ordinary water, purified water, sterilized purified water, water for injection, distilled water for injection, and the like.

  The eye drop according to the present embodiment is provided by being accommodated in an arbitrary container. The container for storing the eye drops according to this embodiment is not particularly limited, and may be made of glass or plastic, for example. Preferably it is made of plastic. Examples of the plastic include polyethylene terephthalate, polyarylate, polyethylene naphthalate, polycarbonate, polyethylene, polypropylene, polyimide, a copolymer of monomers constituting these, and a mixture of these two or more. Polyethylene terephthalate is preferable. In addition, the container that stores the eyedrops according to the present embodiment may be a transparent container that can visually recognize the inside of the container, or an opaque container that is difficult to visually recognize the inside of the container. A transparent container is preferable. Here, the “transparent container” includes both a colorless transparent container and a colored transparent container. The eye drops according to the present embodiment can be used by being housed in a multi-dose form that can be used repeatedly, for example, in a colored transparent plastic container.

  The eye drop according to the present embodiment can be used as a pharmaceutical preparation or a quasi-drug preparation. In addition to the so-called eye drop [however, the eye drop includes an eye drop that can be applied while wearing a contact lens] , Eye wash [however, eye wash contains eye wash that can be washed while wearing contact lens], contact lens composition [contact lens mounting liquid, contact lens care composition (contact lens disinfectant, contact lens use] Preservatives, contact lens cleaning agents, contact lens cleaning preservatives, etc.]. Preferable examples of the present invention include eye drops, artificial tears, eye washes, and contact lens mounting liquids, and eye drops and artificial tears are particularly preferable examples. In addition, when using as a composition for contact lenses, it is applicable to all contact lenses including a hard contact lens and a soft contact lens.

  The eyedrops according to the present embodiment can not only improve subjective symptoms but also suppress the adhesion of foreign matters in order to reduce the feeling of foreign matters. A foreign body sensation means a subjective symptom such as tingling or tingling caused by dry eyes, inappropriate use of contact lenses, allergic conjunctivitis due to adhesion of foreign substances such as pollen and house dust. The foreign body sensation is further enhanced by accompanying inflammation. The eye drops according to this embodiment can be applied for the purpose of prevention or treatment of various symptoms accompanied by a foreign body sensation, and can be caused by allergic conjunctivitis due to the adhesion of foreign substances, from the viewpoint of suppressing the adhesion of foreign substances. It is suitable for foreign body sensation, and particularly suitable for foreign body sensation associated with allergies caused by hay fever or house dust.

  On the other hand, the ophthalmic solution according to the present embodiment can be applied in a state where it is worn on any contact lens including a hard contact lens and a soft contact lens. It is preferable to apply a contact lens, particularly a soft contact lens, particularly a silicone hydrogel contact lens without wearing it. Silicone hydrogel contact lenses are included in soft contact lenses and are both ionic and nonionic, but ionic silicone contact lenses are known to have the property of adsorbing proteins that are allergens. Silicone hydrogel contact lenses are harder than other soft contact lenses, making it easier to feel a foreign body, and more easily causing physical damage to the corneal epithelium. The effect on the effect of alleviating foreign objects is immeasurable. However, it is not recommended that the eye drop according to the present embodiment be instilled while wearing the silicone hydrogel contact lens.

  In another embodiment of the present invention, (A) pranoprofen or a salt thereof is combined with (B) at least one compound selected from the group consisting of anti-allergic agents, anti-inflammatory agents, and water-soluble vitamins. A method for imparting a feeling of foreign substance mitigation to an eye drop, which is characterized by the above, is preferably combined with (C) a cooling agent.

Test Example 1 Measurement of the amount of foreign matter adsorbed on corneal epithelial cells (1)
(1) Test method Each ophthalmic composition was prepared according to the following Table 1, and the influence on foreign matter adsorption to corneal epithelial cells was evaluated. In Table 1, “%” indicating the content means “w / v%” with respect to the whole drug.
Culture medium for each well so that human corneal epithelial cell line HCE-T (RIKEN BioResource Center, No. RCB2280) is placed in a 96-well microplate (Corning) at a rate of 1.0 × 10 ⁵ cells / well. 200 μL each was seeded and cultured at 37 ° C. under 5% CO ₂ for 24 hours. After culturing, the culture medium was removed by suction, 100 μL of each ophthalmic composition each containing 0.05% of albumin fluorescently labeled with FITC was added, and allowed to stand at room temperature for 10 minutes. After the treatment, the solution in the well is removed by suction, 200 μL of phosphate buffer solution is added, the solution in the well is removed by suction and washed, then 100 μL of phosphate buffer solution is added, and a fluorescent plate reader (Fluoroskan Ascent CF The fluorescence value at an excitation wavelength of 485 nm / an emission wavelength of 527 nm was measured using MTX Labsystems. The obtained fluorescence value was converted into the amount of foreign matter (albumin) based on a calibration curve of the amount of foreign matter and the fluorescence value. From the amount of foreign matter obtained, the foreign matter adsorption suppression rate (%) was calculated based on the formula (1).
Foreign matter adsorption suppression rate (%) = [1- (foreign matter amount in each comparative example or example) / (foreign matter amount in comparative example 1)] × 100 (1)
(2) Test results The results are shown in Table 1. Corneal epithelial cells by using Examples 1 to 6 containing (A) pranoprofen and various (B) components against a liquid agent (Comparative Example 1) comprising a buffer solution containing only boric acid and borax. It was confirmed that the adsorption of foreign matter (FITC-labeled albumin) on the surface was significantly suppressed. On the other hand, when (A) the liquid agent containing only pranoprofen was used (Comparative Example 2), the adsorption of foreign substances was not sufficiently suppressed.

Test Example 2 Measurement of the amount of foreign matter adsorbed on corneal epithelial cells (2)
(1) Test Method Each ophthalmic composition was prepared according to Table 2 below, and the effect on foreign matter adsorption to corneal epithelial cells was evaluated in the same manner as in Test Example 1. In Table 2, “%” indicating the content means “w / v%” with respect to the entire drug.
(2) Test results The results are shown in Table 2. By combining (A) pranoprofen, (B) tranilast or olopatadine, and (C) 1-menthol, dl-camphor or borneol, a further remarkable effect of suppressing the adsorption of foreign substances to corneal epithelial cells may be exhibited. It became clear.

Test Example 3 Sensory test: Effect of improving foreign material feeling (1)
(1) Test method Each eye drop was prepared according to a conventional method according to Table 3 below, and filled in a polyethylene terephthalate container. For three subjects who are aware of a foreign body sensation in the eye, (A) ophthalmic solution containing pranoprofen (Comparative Example 3) is applied to the left eye, A single ophthalmic solution (Example 11) contained in the right eye, or (A) an ophthalmic solution containing Planoprofen (Comparative Example 3) in the left eye, (A) Planoprofen, (B) An eye drop containing pyridoxine hydrochloride and (C) l-menthol (Example 12) was each administered once to the right eye, and then the degree of improvement in the feeling of foreign matter in the eye after the eye drop was evaluated. The degree of ocular sensation in the eye was evaluated by the Visual Analog Scale method (VAS method), and the degree of symptom in each group was expressed with the most severe condition as 100%. In Table 3, “%” indicating the content means “w / v%” with respect to the entire drug.

(2) Test results The results are shown in Table 3. When Example 11 containing (A) pranoprofen and (B) dipotassium glycyrrhizinate was used, it was confirmed that it showed a remarkable foreign body feeling improving effect. Further, it was revealed that when Example 12 further containing (C) l-menthol was used, the effect of improving foreign material feeling was more remarkably exhibited.

Test Example 4 Sensory test: Effect of improving foreign material feeling (2)
(1) Test method Each eye drop was prepared according to a conventional method according to the following Table 4, and filled in a polyethylene terephthalate container. For four subjects who are aware of a foreign body sensation in the eye, (A) ophthalmic solution containing pranoprofen (Comparative Example 4) in the left eye, (A) ophthalmic solution containing pranoprofen and (B) tranilast A single dose of the agent (Example 13) to the right eye, or (A) an ophthalmic solution containing pranoprofen (Comparative Example 4) to the left eye, (A) pranoprofen, (B) tranilast and ( C) After the ophthalmic solution containing 1-menthol (Example 14) was each administered once to the right eye, the degree of improvement in the foreign body sensation of the eye after instillation was evaluated. The degree of ocular sensation in the eye was evaluated by the Visual Analog Scale method (VAS method), and the degree of symptom in each group was expressed with the most severe condition as 100%. In Table 4, “%” indicating the content means “w / v%” with respect to the entire drug.
(2) Test results The results are shown in Table 4. When Example 13 containing (A) pranoprofen and (B) tranilast was used, it was confirmed that it showed a remarkable foreign matter feeling improving effect. Further, it was revealed that when Example 14 further containing (C) 1-menthol was used, a further remarkable foreign matter feeling improving effect was exhibited.

Test Example 5. Sensory test: Effect of improving foreign material feeling (3)
(1) Test method Each eye drop was prepared according to a conventional method in accordance with the following Table 5, and filled in a polyethylene terephthalate container. For four subjects who are aware of a foreign body sensation in the eye, (A) ophthalmic solution containing pranoprofen (Comparative Example 5) in the left eye, (A) ophthalmic solution containing pranoprofen and (B) cyanocobalamin After each administration of the agent (Example 15) to the right eye, the degree of improvement in the feeling of foreign matter in the eye after instillation was evaluated. The degree of ocular sensation in the eye was evaluated by the Visual Analog Scale method (VAS method), and the degree of symptom in each group was expressed with the most severe condition as 100%. In Table 5, “%” indicating the content means “w / v%” with respect to the whole drug.

(2) Test results The results are shown in Table 5. When Example 15 containing (A) pranoprofen and (B) cyanocobalamin was used, it was confirmed that it showed a remarkable foreign matter feeling improving effect.

Formulation Example Eye drops were prepared according to the formulations described in Tables 6 and 7 below. By using these eye drops, it is possible to relieve the feeling of foreign objects in the eye. In Tables 6 and 7, “%” indicating the content means “w / v%” with respect to the whole drug.

Claims (7)

Contains the pranoprofen or a salt thereof (A) 0.05w / v%, and at least one anti-allergic agent is selected from the group consisting of (B) Toranirasu preparative及 beauty salt thereof,
(C) further containing a refreshing agent, and as the component (C), containing at least one refreshing agent selected from the group consisting of menthol and camphor,
(A) The total content of the antiallergic agent as component (B) is 10 parts by mass with respect to 1 part by mass of pranoprofen or a salt thereof.
A foreign substance sensation alleviating eye drop that is applied without wearing a silicone hydrogel contact lens (except an eye drop containing diphenhydramine hydrochloride) .   The eye drop of the foreign body sensation according to claim 1, wherein the foreign body sensation is a foreign body sensation as an allergic symptom.   The foreign body sensation mitigation according to claim 1 or 2, wherein the foreign body sensation is a foreign body sensation caused by adhesion or adsorption of at least one foreign material selected from the group consisting of pollen, house dust, protein, and cosmetics. Eye drops.   further containing at least one anti-inflammatory agent selected from the group consisting of ε-aminocaproic acid, allantoin, berberine sulfate, berberine chloride, dipotassium glycyrrhizinate, sodium azulenesulfonate, zinc sulfate, zinc lactate and lysozyme, The foreign substance sensation alleviation eye drop according to any one of claims 1 to 3.   5. The composition according to claim 1, further comprising at least one water-soluble vitamin selected from the group consisting of pyridoxine hydrochloride, cyanocobalamin, sodium flavin adenine dinucleotide, panthenol, calcium pantothenate and sodium pantothenate. The foreign substance sensation alleviating eye drop described in 1. The foreign substance sensation alleviating eye drop according to any one of claims 1 to 5 , wherein the total content of the refreshing agent is 0.0005 to 0.05 w / v% based on the total volume of the eye drop. (A) Any one of Claims 1-6 whose total content of the refreshing agent as (C) component is 0.005-1 mass part with respect to 1 mass part of (A) pranoprofen or its salt content. The foreign substance sensation alleviating eye drop according to claim 1.